Skip to main content
Evidence Snapshot

3',5'-cyclic-AMP phosphodiesterase 4B

CHEMBL275 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:48:06Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL275
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 3',5'-cyclic-AMP phosphodiesterase 4B as ChEMBL target CHEMBL275, mapped to UniProt Q07343. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
3',5'-cyclic-AMP phosphodiesterase 4B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL275
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q07343
3',5'-cyclic-AMP phosphodiesterase 4B
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 3',5'-cyclic-AMP phosphodiesterase 4B matters

As of 2026-09-13

3',5'-cyclic-AMP phosphodiesterase 4B is reviewed as 3',5'-cyclic-AMP phosphodiesterase 4B (UniProt Q07343); the current evidence base includes 6 approved drugs, 3493 compounds, and 351 assays, with lead potency reaching pChEMBL 11.0.

Protein context
3',5'-cyclic-AMP phosphodiesterase 4B

3',5'-cyclic-AMP phosphodiesterase 4B Sequence length is 736 aa.

Review this target as 3',5'-cyclic-AMP phosphodiesterase 4B, mapped to UniProt Q07343. Sequence length is 736 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt Q07343 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 3493 compounds, and 351 assays for this target. The dominant activity type is IC50. CHEMBL569791 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL569791 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
6 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 3',5'-cyclic-AMP phosphodiesterase 4B matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q07343, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3493
Total Compounds
351
Total Assays
6
Approved Drugs
IC50: 3631.0, KI: 199.0, EC50: 4.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL569791
 11.0 IC50 —
No preferred name
CHEMBL3287987
 11.0 IC50 —
No preferred name
CHEMBL4744560
 11.0 IC50 —
No preferred name
CHEMBL4794267
 11.0 IC50 —
No preferred name
CHEMBL3986586
 10.8 IC50 —

Approved Drugs

Structure Compound First Approval
CRISABOROLE
CHEMBL484785
 2016
APREMILAST
CHEMBL514800
 2014
ROFLUMILAST
CHEMBL193240
 2010
IBUDILAST
CHEMBL19449
 1989
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:48:06Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL275